The Impact of Hemodialysis on Humoral and Cellular Immunity in Patients with Renal Failure.

: End-stage renal disease (ESRD) is a growing global health concern, and hemodialysis (HD) remains the most common life-sustaining therapy for patients with advanced kidney failure. Both humoral and cellular immunity are impaired post hemodialysis, leading to immune system dysfunction. : We utilized flow cytometry to quantify cell populations based on surface markers, including CD3 (total T lymphocytes), CD4 (helper T-cells), CD8 (cytotoxic T-cells), CD19 (B lymphocytes), and CD16/CD56 (natural killer (NK) cells). EDTA-blood samples were collected intravenously immediately before and after dialysis. : A consistent decline in CD3 T lymphocytes was observed post hemodialysis. This reduction occurred across both male and female cohorts: = 0.0342 and = 0.0002, respectively. CD8 cytotoxic T-cells decreased significantly post HD, = 0.0003. Conversely, CD4 helper T-cells exhibited a paradoxical increase, = 0.0321. The divergent trends in CD4 and CD8 cells led to a statistically significant increase in the CD4/CD8 ratio post dialysis, = 0.0005. Notably, stratification by gender uncovered that the post-HD changes in CD4 and CD8 T-cells were exclusive to female patients. Females demonstrated a pronounced increase in CD4 cells and a sharper decline in CD8 cells compared to males. CD19 B lymphocytes showed a statistically significant decline post hemodialysis ( < 0.0001). While both genders exhibited reduced B-cell percentages, female patients experienced a more pronounced reduction than males. NK cells were severely depleted post dialysis in both male and female cohorts. : Overall, the immune alterations observed in HD patients, including T-cell reduction, B-cell lymphopenia, and changes in NK cell populations, contribute to the increased risk of infections, malignancy, and cardiovascular disease in this population.